Edgewise Therapeutics (EWTX) Net Cash Flow (2020 - 2026)
Edgewise Therapeutics (EWTX) posted Net Cash Flow of -$27.9 million for Q1 2026, down 284.46% sequentially from $15.1 million in Q4 2025, and down 438.43% YoY from $8.3 million in Q1 2025.
Edgewise Therapeutics (EWTX) Net Cash Flow (2020 - 2026) Analysis & Trends
Edgewise Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$27.9 million in Q1 2026.
- Quarterly Net Cash Flow fell 438.43% year-over-year to -$27.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$16.7 million (down 185.01% YoY) and the FY2025 annual result came in at $19.5 million, up 143.85% from the prior year.
- Net Cash Flow fell to -$27.9 million in Q1 2026 per EWTX's latest filing, from $15.1 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $91.4 million in Q3 2022 and troughed at -$87.8 million in Q4 2022.
- A 5-year average of $1.0 million and a median of $1.3 million in 2024 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 1856.84% in 2022, then surged 582.32% in 2025.
- Over 5 years, Net Cash Flow stood at -$87.8 million in 2022, then soared by 160.56% to $53.1 million in 2023, then plunged by 105.91% to -$3.1 million in 2024, then soared by 582.32% to $15.1 million in 2025, then slumped by 284.46% to -$27.9 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$27.9 million, $15.1 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Edgewise Therapeutics | 4.76 Bn | 4.76 Bn | - | 39.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.11 Mn |
| Jun 30, 2026 | 39.11 Mn |
| Mar 31, 2026 | -27.94 Mn |
| Mar 31, 2026 | -27.94 Mn |
| Dec 31, 2025 | 15.15 Mn |
| Dec 31, 2025 | 15.15 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | -6.52 Mn |
| Jun 30, 2025 | -6.52 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Mar 31, 2025 | 8.26 Mn |
| Dec 31, 2024 | -3.14 Mn |
| Dec 31, 2024 | -3.14 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 13.22 Mn |
| Jun 30, 2024 | 13.22 Mn |
| Mar 31, 2024 | -55.83 Mn |
| Mar 31, 2024 | -55.83 Mn |